9 completed, 1 terminated, 1 withdrawn. 9 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 7, Terminated 1, Withdrawn 1 |
| Phase 2 | 9 | Completed 7, Terminated 1, Withdrawn 1 |
Follow conatumumab: new trials by email Literature Review of conatumumab trials Research Report on conatumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer Birinapant, Conatumumab - Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer | Phase 1 | Completed | TetraLogic Pharmaceuticals | 27 | 2013-11-01 | 2016-01-14 |
| Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Modified FOLFOX6, Conatumumab, Ganitumab - Advanced Solid Tumors, Carcinoid | Phase 2 | Completed | Amgen | 12 | 2011-03-03 | 2021-02-21 |
| QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma FOLFIRI, AMG 655, Placebo - Metastatic Colorectal Cancer | Phase 2 | Completed | NantCell, Inc. | 155 | 2009-03-01 | 2016-10-27 |
| QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors AMG 479, AMG 655 - Colorectal Cancer, Locally Advanced | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 89 | 2009-01-16 | 2024-08-20 |
| Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat AMG 655, Vorinostat, Bortezomib - Hodgkin's Lymphoma, Low Grade Lymphoma | Phase 1 | Completed | Amgen | 33 | 2008-02-01 | 2014-03-05 |
| A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer AMG 655, AMG 655 placebo - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Amgen | 172 | 2008-01-01 | 2016-01-14 |
| Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study Panitumumab, Conatumumab - Colon Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Amgen | 53 | 2008-01-01 | 2014-02-06 |
| Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma AMG 655, Placebo, Doxorubicin - Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma | Phase 1 / Phase 2 | Completed | Amgen | 134 | 2007-11-01 | 2015-05-25 |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer Placebo, AMG 655, Modified FOLFOX6 - Metastatic Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Amgen | 202 | 2007-10-01 | 2014-04-25 |
| QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer Placebo, AMG 479, AMG 655 - Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | NantCell, Inc. | 138 | 2007-06-01 | 2024-10-17 |
| Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer conatumumab, capecitabine, gemcitabine hydrochloride - Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Radiation Therapy Oncology Group | 2013-06-24 |
Colorectal Neoplasms (5) · Neoplasm Metastasis (4) · Carcinoma, Non-Small-Cell Lung (3) · Colonic Neoplasms (3) · Pancreatic Neoplasms (3) · Rectal Neoplasms (3) · Sarcoma (3) · Lymphoma (2) · Adenocarcinoma (1) · Carcinoid Tumor (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Hodgkin Disease (1) · Insulin-Like Growth Factor I, Resistance To (1) · Lymphoma, Large B-Cell, Diffuse (1)
Amgen (6) · NantCell, Inc. (3) · Radiation Therapy Oncology Group (1) · TetraLogic Pharmaceuticals (1)
United States (5) · Poland (2) · Spain (2) · France (1) · Hong Kong (1) · Hungary (1) · India (1) · Italy (1) · Russia (1) · Singapore (1)